title: Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report.
abstract: Molecular targeted therapies (TT) are the cornerstone of metastatic renal cell carcinoma (RCC) treatment. There is a paucity of data on the safety of the radiotherapy (RT)-TT association in a sequential or a concomitant setting. The aim of the present study is to retrospectively assess the safety of the RT-TT association. From 2006 to 2014, data from 84 consecutive patients treated with RT and TT for metastatic RCC were retrospectively collected. RT-TT sequential and concomitant associations were, respectively, defined by a time interval of more than five TT half-lives and less than or equal to five TT half-lives between the last TT administration and RT initiation. Toxicities in the fields of RT were assessed systematically. As many patients received several TT and RT courses, 136 RT-TT associations were analyzed, with 66 sequential and 70 concomitant schemes. RT was mainly delivered on bone (75%) and brain metastases (14.7%). TT were tyrosine kinase inhibitors (73.5%), mTOR inhibitors (19.8%), and monoclonal antibodies (6.7%). With a median follow-up of 9.5 months, whatever the sequence, no grade≥4 toxicity was reported. Two grade 3 toxicities were reported with sequential (3%) and concomitant (2.9%) RT-TT, respectively. Sequential or concomitant RT-TT associations in metastatic RCC do not seem to cause major toxicity.
authors.affiliation: Departments of aRadiotherapy bMedical Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest en Jarez cDepartment of Radiotherapy, General Hospital CH Roanne, Roanne dDepartment of Oncology and Radiotherapy, Val de Grâce Hospital, Paris eDepartment of Medical Oncology, Institut Gustave Roussy, Villejuif fDepartment of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.
authors.forename: Julien
authors.initials: J
authors.lastname: Langrand-Escure
authors.forename: Alexis
authors.initials: A
authors.lastname: Vallard
authors.forename: Romain
authors.initials: R
authors.lastname: Rivoirard
authors.forename: Benoîte
authors.initials: B
authors.lastname: Méry
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Guy
authors.forename: Sophie
authors.initials: S
authors.lastname: Espenel
authors.forename: Jane-Chloé
authors.initials: JC
authors.lastname: Trone
authors.forename: Majed
authors.initials: M
authors.lastname: Ben Mrad
authors.forename: Peng
authors.initials: P
authors.lastname: Diao
authors.forename: Chloé
authors.initials: C
authors.lastname: Rancoule
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Suchaud
authors.forename: Pierre
authors.initials: P
authors.lastname: Fournel
authors.forename: Aline
authors.initials: A
authors.lastname: Guillot
authors.forename: Cyrus
authors.initials: C
authors.lastname: Chargari
authors.forename: Bernard
authors.initials: B
authors.lastname: Escudier
authors.forename: Sylvie
authors.initials: S
authors.lastname: Négrier
authors.forename: Nicolas
authors.initials: N
authors.lastname: Magné
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D012189:Retrospective Studies; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D011505:Protein-Tyrosine Kinases; D058570:TOR Serine-Threonine Kinases